The first two patients have been randomized in Phase 2 of the OVATION 2 trial testing the immunotherapy candidate GEN-1 in newly diagnosed advanced ovarian cancer. Celsion Corporation, the immunotherapy’s developer, expects to enroll up to 118 patients in this second part of the study by the end of 2021, and will provide clinical updates throughout the course of treatment. “We are delighted to have begun enrolling patients in the Study and look to achieve our goal…
You must be logged in to read/download the full post.
The post First Ovarian Cancer Patients Dosed in Phase 2 of OVATION 2 Trial appeared first on BioNewsFeeds.